Understanding how HPV helps head and neck cancer evade the immune system

Immune receptor degradation for immune evasion of head and neck cancer

NIH-funded research Henry Ford Health + Michigan State University Health Sciences · NIH-11073198

This study is looking at how the HPV virus helps head and neck cancers avoid the immune system, focusing on a protein called MARCHF8 that makes it harder for the immune system to fight the cancer, and it aims to find new ways to improve treatments that boost the immune response against these cancers.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionHenry Ford Health + Michigan State University Health Sciences NIH-funded
Lab location1 site (East Lansing, United States)
Project IDNIH-11073198 on NIH RePORTER

What this research studies

This research investigates the mechanisms by which human papillomavirus (HPV) contributes to the immune evasion of head and neck cancers. It focuses on the role of a protein called MARCHF8, which is activated by HPV and leads to the degradation of important immune receptors on cancer cells. By studying this process, the researchers aim to identify potential therapeutic targets that could enhance the effectiveness of existing immunotherapies. The approach includes laboratory experiments that manipulate MARCHF8 levels in cancer cells to observe changes in immune receptor expression and T cell responses.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with HPV-positive head and neck squamous cell carcinoma.

Not a fit: Patients with HPV-negative head and neck cancers may not receive direct benefits from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved immunotherapy strategies for patients with HPV-positive head and neck cancers.

How similar studies have performed: Other research has shown promising results in targeting immune evasion mechanisms in various cancers, suggesting that this approach could be effective.

Where this research is happening

East Lansing, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.